A Real-world Study of Fruquintinib in the Cross-line Treatment of Refractory mCRC
This is a real-world study. Patients with metastatic colorectal cancer who have progressed (PD) after third-line treatment with fruquintinib combined with PD-1 inhibitors will receive fruquintinib combined with TAS-102 as fourth-line therapy. The objective of this study was to observe the efficacy and safety of cross-line（from third to fourth line）treatment with fruquinitinib.
⁃ \-
⁃ To be enrolled in this study, patients must meet all of the following criteria:
• Age ≥18 years, ≤75 years;
• No gender limitation;
• Patients with metastatic colorectal cancer confirmed by histopathology had previously received 2-line system therapy with fluorouracil, oxaliplatin, irinotecan, anti-VEGF, anti-EGFR (RAS and BRAF wild type) (treatment with anti-VEGF-TKI is not allowed), and had received fruquinitinib combined with PD-1 inhibitors for third-line treatment. After progression (PD) (confirmed by RECIST 1.1 ), fruquinitinib combined with TAS-102 as fourth-line therapy was received.
• Expected survival ≥12 weeks
• Must have at least one measurable lesion (RECIST1.1).
• Full organ and bone marrow function.